Trials / Completed
CompletedNCT03568929
Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma
Non-interventional Study to Assess the Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma (FL)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 257 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idelalisib | Tablets administered according to the product information and treatment guidelines in routine clinical practice |
Timeline
- Start date
- 2018-05-25
- Primary completion
- 2021-10-29
- Completion
- 2021-10-29
- First posted
- 2018-06-26
- Last updated
- 2021-11-19
Locations
88 sites across 10 countries: Belgium, France, Germany, Greece, Ireland, Italy, Portugal, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT03568929. Inclusion in this directory is not an endorsement.